Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Systemic sclerosis
If a patient with limited scleroderma presents with the three active domains including skin thickening, inflammatory joint pain, and ILD would you consider starting Actemra?
Related Questions
If a patient has progression of scleroderma-ILD on MMF alone, and you are planning to start tocilizumab, would you continue MMF at a lower dose to maintain skin softening?
How do you approach the significance of +RNP III antibody in a patient with positive ANA but no other signs or symptoms of systemic sclerosis?
In patients with diffuse scleroderma and symptomatic lower extremity venous insufficiency, would you recommend treatment with endovenous laser/ablation?
How do you approach initial steroid dosing in patients with eosinophilic fasciitis?
What is your preferred management approach for scleroderma renal crisis in a patient with a history of anaphylaxis to ACE inhibitors?
How do you approach management of a patient presenting with clinical manifestations of systemic sclerosis (cutaneous involvement, Raynaud’s phenomenon, and pulmonary arterial hypertension) but negative serologies?
What Barrett's Esophagus screening protocol do you follow for patients with scleroderma given the increased risk of reflux and esophageal stasis?
What is the clinical significance of an isolated anti-centromere B antibody in a patient with pulmonary fibrosis but no other features of systemic sclerosis?
What are some important considerations for use of ACE inhibition in scleroderma renal crisis patients who require dialysis?
What treatment regimen would you recommend for a patient with biopsy-proven giant cell arteritis and diffuse cutaneous systemic sclerosis?
